// App-Quantinova.ai

2379 : Lack Of Anti-Xa Assay Standardization Results In Significant Dose Variation In Neonates and Children Receiving Enoxaparin

Researchers

Presenter

  • Lindsey A. Greene

Principal Investigators

  • Connie Law

  • Mike Jung

  • Sara Walton

  • Leslie J. Raffini

Medical Centers

  • Clinical Pharmacy, The Childre-s Hospital of Philadelphia, Philadelphia, PA

  • Department of Pathology, The Children's Hospital of Philadelphia, Philadelphia, PA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Venous thrombosis

Biomarkers

  • DNA Damage Inducible Transcript 3

Drug/Treatment

  • Enoxaparin

  • Enoxaparin sodium

  • Hemostatic Solution

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved